Jpmorgan Chase & CO Pro Qr Therapeutics N.V. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 300 shares of PRQR stock, worth $801. This represents 0.0% of its overall portfolio holdings.
Number of Shares
300
Previous 314
4.46%
Holding current value
$801
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding PRQR
# of Institutions
52Shares Held
17.4MCall Options Held
37.7KPut Options Held
21.3K-
Privium Fund Management B.V.5.63MShares$15 Million2.56% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.63MShares$9.68 Million0.01% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA1.84MShares$4.9 Million0.14% of portfolio
-
M28 Capital Management LP Stamford, CT1.02MShares$2.72 Million1.76% of portfolio
-
Dafna Capital Management LLC Los Angeles, CA906KShares$2.42 Million0.42% of portfolio
About ProQR Therapeutics N.V.
- Ticker PRQR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,362,096
- Market Cap $191M
- Description
- ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...